CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.

scientific article published on 31 March 2009

CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3324/HAEMATOL.2008.002691
P932PMC publication ID2688582
P698PubMed publication ID19336735
P5875ResearchGate publication ID24248585

P50authorJane AndersonQ21544772
Andrew N PhillipsQ87677848
Philippa EasterbrookQ90656517
Mark BowerQ41594532
Caroline SabinQ42249738
Kholoud PorterQ53124393
Deenan PillayQ57899870
Chloe OrkinQ87418404
P2093author name stringJohn Walsh
Martin Fisher
Brian Gazzard
Loveleen Bansi
Richard Gilson
Iain Reeves
Margaret Johnson
Clifford Leen
Mark Gompels
Teresa Hill
Achim Schwenk
UK CHIC Steering Committee
P2860cites workHIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell countsQ33280133
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adultsQ33925343
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapyQ34093851
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapyQ34403321
Immune reconstitution after highly active anti-retroviral treatment of HIV infection.Q34483191
Trends in cancer risk among people with AIDS in the United States 1980-2002.Q34569368
Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphomaQ35174152
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Q36653838
Indicator disease-guided testing for HIV--the next step for Europe?Q37192570
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapyQ38491355
Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort StudyQ38499506
Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort StudyQ38638675
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapyQ40744123
Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy.Q45179311
Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapyQ45710801
Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survivalQ46164918
Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphomaQ49273653
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelQ50105738
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapyQ56528095
The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) StudyQ57181218
Incidence of AIDS-Defining Cancers After AIDS Diagnosis Among People with AIDS in Italy, 1986–1998Q58281812
Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversionQ59119701
Immune deficiency and risk for malignancy among persons with AIDSQ73224505
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapyQ73794336
P433issue6
P921main subjectHIVQ15787
P304page(s)875-880
P577publication date2009-03-31
P1433published inHaematologicaQ5638209
P1476titleCD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
P478volume94

Reverse relations

cites work (P2860)
Q50101286A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma
Q38029093A review of the role of lymphoma markers and occupational and environmental exposures
Q37684247An AIDS-defining neoplasm in a 30-year-old man on highly active antiretroviral therapy: a forgotten diagnosis?
Q40250347Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada
Q64128653Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
Q45358998Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma
Q34661370Cancer biomarkers in HIV patients
Q36102589Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010
Q33863292Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy
Q47266595Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.
Q35112218Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes
Q34498993Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution
Q35830555Effects of long-term use of antiretroviral therapy on the prevalence of oral Epstein-Barr virus
Q42719779Extranodal lymphoma masquerading as carcinoma of the breast in an HIV-positive male patient
Q40043098Fever and generalised lymphadenopathy in an HIV-positive patient: a diagnostic challenge.
Q46245165HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production.
Q56112360HIV-related lymphoma
Q37567836Immunotherapy for HIV-associated non-Hodgkin's lymphoma.
Q41990454Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
Q92073643Non-Hodgkin lymphoma in people with HIV
Q41101979PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement
Q40927354Remission of human immunodeficiency virus-related lymphoma in association with immune reconstitution on anti-retroviral therapy, without chemotherapy
Q44314941Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy
Q28081273Spontaneous Regression of Refractory Diffuse Large B-Cell Lymphoma with Improvement in Immune Status with ART in a Patient with HIV: A Case Report and Literature Review
Q37106782Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.
Q38615024The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients
Q95289784The Role of Microbial Translocation and Immune Activation in AIDS-Associated Non-Hodgkin Lymphoma Pathogenesis: What Have We Learned?
Q38210131Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).